Testing effectiveness (Phase 2)Study completedNCT03192202What this trial is testingAFM13 in Relapsed/Refractory Cutaneous LymphomasWho this might be right forLymphoma, T-Cell, Cutaneous Ahmed Sawas 18
Testing effectiveness (Phase 2)Looking for participantsNCT04083495What this trial is testingCD30 CAR for Relapsed/Refractory CD30+ T Cell LymphomaWho this might be right forPeripheral T Cell Lymphoma UNC Lineberger Comprehensive Cancer Center 20
Testing effectiveness (Phase 2)Looking for participantsNCT04803201What this trial is testingTesting the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaWho this might be right forAngioimmunoblastic T-cell LymphomaEnteropathy-Associated T-Cell LymphomaFollicular T-Cell Lymphoma+4 more Alliance for Clinical Trials in Oncology 170
Testing effectiveness (Phase 2)Study completedNCT02497131What this trial is testingStudy on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL PatientsWho this might be right forLymphatic Diseases Fondazione Italiana Linfomi - ETS 25
Post-approval studies (Phase 4)Study completedNCT05442554What this trial is testingBrentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell LymphomaWho this might be right forT-Cell Lymphoma Takeda 10
Early research (Phase 1)Active Not RecruitingNCT04288726What this trial is testingAllogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive LymphomasWho this might be right forExtranodal Natural Killer/T-Cell Lymphoma, Nasal TypeClassical Hodgkin Lymphoma Baylor College of Medicine 27
Testing effectiveness (Phase 2)UnknownNCT02274584What this trial is testingCAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)Who this might be right forLymphomas Peking University 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT03113500What this trial is testingBrentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell LymphomaWho this might be right forAdult T-Cell Leukemia/LymphomaAnaplastic Large Cell Lymphoma, ALK-NegativeAnaplastic Large Cell Lymphoma, ALK-Positive+8 more City of Hope Medical Center 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT01352520What this trial is testingSGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)Who this might be right forCD-30 Positive Anaplastic Large T-cell Cutaneous LymphomaLymphoma, Primary Cutaneous Anaplastic Large CellLymphomatoid Papulosis+5 more M.D. Anderson Cancer Center 79
Testing effectiveness (Phase 2)Study completedNCT04569032What this trial is testingBrentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 ExpressionWho this might be right forPeripheral T-cell Lymphoma Seagen, a wholly owned subsidiary of Pfizer 82
Early research (Phase 1)Active Not RecruitingNCT03602157What this trial is testingStudy of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCLWho this might be right forLymphomaImmune System DiseasesImmunoproliferative Disorders+10 more UNC Lineberger Comprehensive Cancer Center 43
Not applicableLooking for participantsNCT07074457What this trial is testingChidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL PatientsWho this might be right forCD30+ Peripheral T-cell Lymphoma The First Affiliated Hospital of Soochow University 47
Early research (Phase 1)Study completedNCT03302728What this trial is testingBrentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin LymphomaWho this might be right forLymphoma, T-Cell, CutaneousLymphoma, T-Cell, PeripheralHodgkin Lymphoma Peter MacCallum Cancer Centre, Australia 6
Testing effectiveness (Phase 2)Ended earlyNCT02499627What this trial is testingBendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage SettingWho this might be right forLymphatic Diseases Fondazione Italiana Linfomi - ETS 43
Testing effectiveness (Phase 2)UnknownNCT05316246What this trial is testingEfficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell LymphomaWho this might be right forNK/T Cell Lymphoma Nos Shanghai Zhongshan Hospital 40
Testing effectiveness (Phase 2)Study completedNCT01396070What this trial is testingBrentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression LevelWho this might be right forNon-Hodgkin Lymphoma (NHL)Cutaneous LymphomaCutaneous T-cell Lymphoma (CTCL)+2 more Youn Kim 36
Large-scale testing (Phase 3)Study completedNCT01578499What this trial is testingTrial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)Who this might be right forPrimary Cutaneous Anaplastic Large Cell LymphomaMycosis FungoidesCutaneous T-Cell Lymphoma Millennium Pharmaceuticals, Inc. 131
Not applicableEnded earlyNCT01841021What this trial is testingPilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30Who this might be right forPeripheral T-Cell Lymphoma H. Lee Moffitt Cancer Center and Research Institute 1
Testing effectiveness (Phase 2)Study completedNCT04074746What this trial is testingModified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin LymphomasWho this might be right forRecurrent Anaplastic Large Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Classic Hodgkin Lymphoma+7 more M.D. Anderson Cancer Center 45
Testing effectiveness (Phase 2)Study completedNCT01716806What this trial is testingBrentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)Who this might be right forHodgkin DiseasePeripheral T Cell Lymphoma Seagen Inc. 131